Watch Dr. Cyrus Javan of NIAID's Division of AIDS explain the importance of the STOMP trial

Tuesday, October 10, 2023 The STOMP trial evaluates an antiviral for mpox Following a peak in the summer of 2022, new infections in the mpox clade IIb outbreak have decreased, due in part to the rapid availability and uptake of vaccines and other preventive measures. However, mpox remains a health threat, and no treatment has been proven safe and effective for people experiencing mpox disease. NIAID launched the STOMP trial to determine whether the antiviral drug tecovirimat can safely and effectively treat mpox. Arzhang Cyrus Javan, M.D., M.P.H., D.T.M.H., a medical officer in NIAID's Division of AIDS, explained the importance of the STOMP trial in a short video. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107